EPO Revokes Controversial Patent For Breast Cancer Screening
The patent covers a test to predict if a woman is at high risk of developing breast cancer by looking for mutations in a gene called BRCA1.
“After a public hearing of all parties to the opposition proceedings against the patent, the division - a panel composed of three patent examiners and a legal expert - concluded that the grounds...
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login